Kintara Therapeutics Inc (Nasdaq: KTRA), a United States-based biopharmaceutical company, announced on Wednesday that it has named Mario Lacouture as MD to the REM-001 Scientific Advisory Board.

Dr Lacouture will initially concentrate on Cutaneous Metastatic Breast Cancer (CMBC).

Dr Lacouture is serving as the director of the Oncodermatology Program at the Memorial Sloan Kettering Cancer Center. He is also a professor of dermatology at Weill Cornell Medicine in New York City. He has a medical degree from Javeriana University in Bogota, Colombia and completed an internship in General Surgery at The Cleveland Clinic, residency in dermatology at The University of Chicago, and postdoctoral work at Brigham and Women's Hospital in Boston.